易普利姆玛治疗晚期黑色素瘤有效性和安全性的Meta分析

发布时间：2018-03-09 22:05

本文选题：易普利姆玛　切入点：晚期黑色素瘤　出处：《中国新药杂志》2017年08期 　论文类型：期刊论文

【摘要】：目的:系统评价易普利姆玛的有效性和安全性。方法:计算机检索PubMed,Cochrane Library,Embase,中国知网、万方和维普数据库。由2位研究者按照纳入和排除标准筛选文献、提取资料和质量评价后,采用RevMan 5.3软件进行Meta分析。结果:纳入4项随机对照试验,共2 622例病例。Meta分析结果显示:与对照组相比,易普利姆玛组1年无进展生存率(RR=0.94,95%CI:0.91~0.98,P=0.001)、1年总生存率(RR=0.79,95%CI:0.72~0.87,P0.000 01)较高,具有统计学差异。2年无进展生存率无统计学差异(RR=0.99,95%CI:0.97~1.01,P=0.45)及3年总生存率(RR=0.93,95%CI:0.84~1.03,P=0.17)均无统计学差异。易普利姆玛组患者皮疹(RR=2.43,95%CI:1.64~3.61,P0.000 01)、瘙痒(RR=2.35,95%CI:1.67~3.29,P0.000 01)、腹泻(RR=1.82,95%CI:1.47~2.25,P0.000 01)、结肠炎(RR=11.21,95%CI:6.20~20.30,P0.000 01)、丙氨酸氨基转移酶增高(RR=3.57,95%CI:1.92~6.62,P0.000 1)、天门冬氨酸氨基转移酶增高(RR=3.81,95%CI:2.85~5.09,P0.000 01)的发生率均较高。结论:与对照组相比,易普利姆玛可提高患者1年无进展生存率、1年总生存率,但在2年无进展生存率及3年总生存率未显示出优势,且易普利姆玛增加了患者出现皮疹、瘙痒、腹泻、结肠炎和转氨酶升高的风险。
[Abstract]:Objective: to systematically evaluate the efficacy and safety of Eprimma. Methods: a computer-based search of the PubMedCochrane Library Embase, China knowledge Network, Wanfang and Weipu databases was conducted. The literature was selected by two researchers according to the inclusion and exclusion criteria, and the data were extracted and the quality evaluated. Results: a total of 2 622 cases were enrolled in 4 randomized controlled trials. Meta-analysis results showed that compared with the control group, the 1 year progression free survival rate of the Iprimma group was higher than that of the control group, and the 1 year overall survival rate was higher than that of the control group, and the 1 year overall survival rate was higher than that of the control group. There was no statistical difference in the 2-year progression-free survival rate. There was no statistical difference in the 2-year progression-free survival rate (RRR0.9395CI0.971P0.45) and the overall 3-year survival rate (RR0.9395CI0.841.0395 CI0.841.03P0.17). There was no statistical difference in the 2-year progression-free survival rate. No statistical difference was found in the 2-year progressive survival rate. No statistical difference was found in the 2-year progression-free survival rate. There was no statistical difference in the 2-year progressive survival rate. There was no statistical difference in the 2-year progression-free survival rate. There was no statistical difference in the 2-year progression-free survival rate. There was no statistical difference in the 2-year progression-free survival rate. There was no statistical difference in the 2-year progression-free survival rate. There was no statistical difference in the 2-year progression-free survival rate. No statistical difference was found in the 2-year progression survival rate. There was no statistical difference in the 2-year progression survival rate. There was no statistical difference in the 2-year progression survival rate. There was no statistical difference in the 2-year progress-free survival rate. The incidence of RRN 3.5795% CIW 1.92C6.62KP0.000 and aspartate aminotransferase RRN 3.8195% is higher than that of the control group. Conclusion: compared with the control group, the incidence of RRN is higher than that of the control group. The 1-year progression-free survival rate and 1-year overall survival rate were improved by Iprimma, but the 2-year progression-free survival rate and 3-year overall survival rate did not show any advantage, and Iprimma increased the incidence of rash, pruritus and diarrhea. Increased risk of colitis and transaminase.
【作者单位】：重庆医科大学附属第一医院皮肤科;
【分类号】：R739.5

【相似文献】